VISTA的免疫调节功能。
Immunoregulatory functions of VISTA.
作者信息
Nowak Elizabeth C, Lines J Louise, Varn Frederick S, Deng Jie, Sarde Aurelien, Mabaera Rodwell, Kuta Anna, Le Mercier Isabelle, Cheng Chao, Noelle Randolph J
机构信息
Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
出版信息
Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525.
Abstract
Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
摘要
随着证明疗效的临床试验完成，利用负性检查点调节因子（NCRs）进行癌症免疫治疗已引起广泛关注。虽然单药治疗的结果令人信服，但为了提高治疗反应率，人们越来越重视联合治疗。VISTA（含V结构域免疫球蛋白的T细胞活化抑制因子）是最近发现的NCRs之一。在这篇综述中，我们描述了该分子在癌症免疫治疗背景下的功能。我们还讨论了可能影响抗VISTA抗体在联合治疗中应用的因素，以及基因组分析如何有助于提供治疗指征。
相似文献
1
Immunoregulatory functions of VISTA.VISTA的免疫调节功能。
Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525.
2
VISTA: A Novel Checkpoint for Cancer Immunotherapy.VISTA：癌症免疫治疗的新靶点。
Drug Discov Today. 2024 Jul;29(7):104045. doi: 10.1016/j.drudis.2024.104045. Epub 2024 May 24.
3
New checkpoints in cancer immunotherapy.癌症免疫疗法中的新检查点。
Immunol Rev. 2017 Mar;276(1):52-65. doi: 10.1111/imr.12524.
4
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.免疫检查点分子 VISTA 在自身免疫性疾病和癌症中的表达及免疫调节作用。
Cytokine Growth Factor Rev. 2020 Apr;52:1-14. doi: 10.1016/j.cytogfr.2020.02.002. Epub 2020 Feb 5.
5
Acidity changes immunology: a new VISTA pathway.酸度改变免疫学：一条新的VISTA通路。
Nat Immunol. 2020 Jan;21(1):13-16. doi: 10.1038/s41590-019-0563-2.
6
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.VISTA：一种新型免疫治疗靶点，可使先天免疫和适应性免疫正常化。
Semin Immunol. 2019 Apr;42:101308. doi: 10.1016/j.smim.2019.101308.
7
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.VISTA 是一种新型广谱负检查点调节剂，可用于癌症免疫治疗。
Cancer Immunol Res. 2014 Jun;2(6):510-7. doi: 10.1158/2326-6066.CIR-14-0072.
8
Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.未来展望：基于人 V -set 免疫调节受体的新型免疫疗法用于消化系统肿瘤。
Int J Mol Sci. 2023 Jun 9;24(12):9945. doi: 10.3390/ijms24129945.
9
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.VISTA 免疫调节作用在绕过癌症免疫治疗中的作用：更新。
Life Sci. 2022 Dec 1;310:121083. doi: 10.1016/j.lfs.2022.121083. Epub 2022 Oct 17.
10
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.三种免疫检查点（VISTA、CTLA-4、PD-1）通路对鳞状细胞癌抗肿瘤反应的不同贡献。
Oral Oncol. 2016 Jun;57:54-60. doi: 10.1016/j.oraloncology.2016.04.005. Epub 2016 May 3.
引用本文的文献
1
Targeting myeloid cells to improve cancer immune therapy.靶向髓样细胞以改善癌症免疫治疗。
Front Immunol. 2025 Jul 31;16:1623436. doi: 10.3389/fimmu.2025.1623436. eCollection 2025.
2
Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis.PD-1/PD-L1在重症肌无力中的免疫调节作用：来自外周血单个核细胞分析的见解
FASEB J. 2025 Aug 15;39(15):e70827. doi: 10.1096/fj.202500887R.
3
Unveiling the mechanisms of CEBPD-orchestrated TAM polarization through RGS2/PAR2 pathway and its impact on ICB efficacy in clear cell renal cell carcinoma.揭示通过RGS2/PAR2途径由CEBPD精心调控的肿瘤相关巨噬细胞极化机制及其对透明细胞肾细胞癌免疫检查点阻断疗效的影响。
J Immunother Cancer. 2025 Jul 13;13(7):e010898. doi: 10.1136/jitc-2024-010898.
4
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
5
Therapeutic targeting of tumour-associated macrophage receptors.肿瘤相关巨噬细胞受体的治疗靶向作用
Immunother Adv. 2025 Mar 11;5(1):ltaf009. doi: 10.1093/immadv/ltaf009. eCollection 2025.
6
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families.揭示不同蛋白质家族中免疫检查点蛋白的作用机制和治疗潜力。
Front Immunol. 2025 Apr 28;16:1499663. doi: 10.3389/fimmu.2025.1499663. eCollection 2025.
7
Immune checkpoint for pregnancy.妊娠的免疫检查点。
Semin Immunopathol. 2025 May 2;47(1):26. doi: 10.1007/s00281-025-01051-y.
8
FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions.VISTA免疫检查点激活FOXO1信号通路会抑制肺部2型固有淋巴细胞的功能。
J Clin Invest. 2025 Jan 2;135(4):e184932. doi: 10.1172/JCI184932.
9
VISTA in hematological malignancies: a review of the literature.VISTA在血液系统恶性肿瘤中的研究：文献综述
Front Immunol. 2024 Dec 17;15:1466839. doi: 10.3389/fimmu.2024.1466839. eCollection 2024.
10
A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.一对从免疫耐受到免疫治疗的有前景的免疫检查点PSGL-1和VISTA。
Biomark Res. 2024 Dec 2;12(1):151. doi: 10.1186/s40364-024-00693-8.
本文引用的文献
1
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.肿瘤免疫谱分析可预测人类黑色素瘤对抗PD-1治疗的反应。
J Clin Invest. 2016 Sep 1;126(9):3447-52. doi: 10.1172/JCI87324. Epub 2016 Aug 15.
2
Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.gp96-Ig/共刺激分子（OX40L、ICOSL 或 4-1BBL）联合疫苗可改善 T 细胞的初始激活并增强免疫、记忆和肿瘤消除。
Cancer Immunol Res. 2016 Sep 2;4(9):766-78. doi: 10.1158/2326-6066.CIR-15-0228. Epub 2016 Jun 30.
3
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.三种免疫检查点（VISTA、CTLA-4、PD-1）通路对鳞状细胞癌抗肿瘤反应的不同贡献。
Oral Oncol. 2016 Jun;57:54-60. doi: 10.1016/j.oraloncology.2016.04.005. Epub 2016 May 3.
4
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.结直肠癌中免疫细胞浸润的基因组关联
Cell Rep. 2016 Apr 26;15(4):857-865. doi: 10.1016/j.celrep.2016.03.075. Epub 2016 Apr 14.
5
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.转移性黑色素瘤中抗PD-1治疗反应的基因组和转录组特征
Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.
6
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.克隆性新抗原引发T细胞免疫反应性以及对免疫检查点阻断的敏感性。
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
7
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.pVAC-Seq：一种基于基因组引导的计算机模拟方法来鉴定肿瘤新抗原。
Genome Med. 2016 Jan 29;8(1):11. doi: 10.1186/s13073-016-0264-5.
8
Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles.乳腺癌的综合分析揭示了预后造血活性和患者特异性免疫反应谱。
Nat Commun. 2016 Jan 4;7:10248. doi: 10.1038/ncomms10248.
9
Combination cancer immunotherapies tailored to the tumour microenvironment.针对肿瘤微环境的定制化癌症免疫疗法组合。
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. doi: 10.1038/nrclinonc.2015.209. Epub 2015 Nov 24.
10
CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.CD39表达可识别终末耗竭的CD8 + T细胞。
PLoS Pathog. 2015 Oct 20;11(10):e1005177. doi: 10.1371/journal.ppat.1005177. eCollection 2015 Oct.
Zotero 插件